care providers in making challenging disease management decisions. More comparative data are needed to inform treatment selection. Several ongoing trials, including a trial to compare a TNFi biologic combination therapy with a TNFi biologic monotherapy and MTX monotherapy , will inform treatment decisions. We anticipate future updates to the guideline when new evidence is available.